Extended adjuvant therapy for early‐stage breast cancer: Are there markers for its use?

2019 ◽  
Vol 25 (1) ◽  
pp. 7-8
Author(s):  
Natalie Klar ◽  
Adam Brufsky
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Extended Adjuvant Therapy

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.

1998 ◽  
Vol 16 (4) ◽  
pp. 1380-1387 ◽  
Author(s):  
C Lindley ◽  
S Vasa ◽  
W T Sawyer ◽  
E P Winer
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Adjuvant Therapy ◽  
Sexual Function ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Systemic Adjuvant Therapy

PURPOSE To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS Eighty-six patients who had completed systemic adjuvant therapy for early-stage breast cancer between 1988 and 1991 were surveyed by written questionnaire and telephone interview. Sociodemographic information was obtained for each patient, and patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), the Medical Outcomes Study (MOS) Short Form 36 (SF-36), a series of questions regarding sexual function, and a survey about preferences for adjuvant therapy in relation to possible benefit. RESULTS The mean FLIC score among all patients was 138.3 (+/- 12.2), which suggests a high level of QOL. The reported frequency of moderate to severe symptoms was generally low (ie, < 15%), with fatigue (31.4%), insomnia (23.3%), and local numbness at the site of surgery (22.1%) occurring with greatest frequency. Patients reported a wide range of sexual difficulties. Preference assessment showed that more than 65% of patients were willing to undergo 6 months of chemotherapy for a 5% increase in likelihood of cancer cure. CONCLUSION Self-rated QOL in breast cancer patients 2 to 5 years following adjuvant therapy was generally favorable. Less than one third of patients reported moderate to severe symptoms. Selected aspects of sexual function appeared to be compromised. The majority of patients indicated a willingness to accept 6 months of chemotherapy for small to modest potential benefit.

Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 1094-1094
Author(s):  
J. Li ◽  
M. E. Melisko ◽  
P. N. Munster ◽  
M. Pelayo ◽  
M. M. Moasser ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Adjuvant Therapy ◽  
Tumor Cells ◽  
Early Stage ◽  
Disseminated Tumor Cells ◽  
Early Stage Breast Cancer

Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 524-524
Author(s):  
Michael Gnant ◽  
Hiroji Iwata ◽  
Anna Elizabeth Bashford ◽  
Robert Separovic ◽  
Adolfo Murias ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Phase Iii ◽  
Her2 Breast Cancer ◽  
Extended Adjuvant Therapy
Sign in / Sign up

Export Citation Format

Share Document